IDRx is developing IDRX-42, an oral KIT tyrosine kinase inhibitor targeting specific mutations in gastrointestinal stromal tumors (GIST) to enhance treatment efficacy. The company addresses the significant unmet medical need for effective therapies in GIST, where current standards of care have remained unchanged for nearly two decades.
Funding
$242M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BGFounders
Product
Problem
Gastrointestinal stromal tumors (GIST) driven by KIT mutations often develop resistance to existing tyrosine kinase inhibitors (TKIs), and current standards of care have remained largely unchanged for two decades, creating a significant unmet need for more effective therapies.
Solution
IDRx is developing IDRX-42, an oral, small molecule KIT TKI designed to selectively target prevalent KIT mutations that drive initial tumor growth or confer resistance to currently available therapies in GIST. IDRX-42 aims to improve outcomes for patients with GIST as a first- or second-line therapy. The company is currently evaluating IDRX-42 in an open-label Phase 1/1b clinical trial (StrateGIST 1) for advanced GIST and plans to initiate StrateGIST 3, a global, randomized, open-label Phase 3 registrational trial, to evaluate IDRX-42 as a second-line therapy.
Target Audience
The primary target audience includes patients with gastrointestinal stromal tumors (GIST) who have developed resistance to existing therapies or require first-line treatment, and the oncologists who treat them.
Features
- Oral small molecule KIT tyrosine kinase inhibitor (TKI)
- Designed to selectively target prevalent KIT mutations in GIST
- Clinical development as a monotherapy for GIST
- Being evaluated in Phase 1/1b clinical trial (StrateGIST 1) for advanced GIST
- Planned Phase 3 registrational trial (StrateGIST 3) as a second-line therapy